Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07317154 · ClinicalTrials.gov registry record · Phase 1
Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients
A Phase 1 study of Recurrent Respiratory Papillomatosis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT07317154 is a Phase 1 study of Recurrent Respiratory Papillomatosis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 9 participants, below the 37-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07317154, a Phase 1 study of Recurrent Respiratory Papillomatosis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Conditions Studied
Interventions
- BIOLOGICAL Immunotherapy
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-01 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07317154
The ClinicalTrials.gov registry entry for NCT07317154 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 6 other Recurrent Respiratory Papillomatosis trials with a reported enrollment target (76% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Respiratory Papillomatosis appearing as the primary indexed condition, and to 1 intervention - of which Immunotherapy is the first listed.
NCT07317154 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT07317154 about?
NCT07317154 is a clinical study titled "Autologous Dendritic Cell Vaccine For Recurrent Respiratory Papillomatosis (RRP) Patients". The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
What is the current status of trial NCT07317154?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-01. Estimated completion is 2027-02.
What conditions does trial NCT07317154 study?
This clinical trial studies the following conditions: Recurrent Respiratory Papillomatosis.
What interventions are being tested in trial NCT07317154?
The interventions under investigation include: Immunotherapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT07317154?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07317154 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Respiratory Papillomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis
ACTIVE NOT RECRUITING · Phase 1
-
Zopa Retreatment and Vector Shedding in Adults With RRP
RECRUITING · Phase 4
-
Merck IIT: RRP Pembro and Lenvatinib
RECRUITING · Early Phase 1
-
The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)
RECRUITING
-
Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients
ACTIVE NOT RECRUITING · Phase 2
-
Avelumab for People With Recurrent Respiratory Papillomatosis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.